查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1573880

特發性肺纖維化治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Idiopathic Pulmonary Fibrosis Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 268 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年，全球特發性肺纖維化治療市場估值為30億美元，預計2024年至2032年複合年成長率為6.9%。 IPF）發病率上升所推動的人口和環境因素。

隨著全球人口老化，特發性肺纖維化（IPF）的流行對全球醫療保健系統提出了挑戰。美國國立衛生研究院的數據顯示，IPF 在男性中更為常見，北美的發生率範圍為每 10,000 人 2.40 至 2.98 例。這種流行刺激了治療創新，包括標靶治療和免疫療法，擴大了患者護理選擇並推動了市場擴張。

診斷技術的進步對於及時發現和管理 IPF 至關重要。先進的影像系統和非侵入性工具使醫療保健專業人員能夠更早地識別 IPF。早期檢測可以及時干預，改善患者治療效果並推動市場成長。

整個特發性肺纖維化治療產業根據治療類型、給藥途徑、年齡層、最終用途和地區進行分類。

2023年，藥品類細分市場以18億美元的估值引領市場。這種成長歸因於意識的提高、及時的診斷和藥物療效的提高。 NIH資料表明，美國每年約有 10 萬人被診斷出患有 IPF。藥物類別包括抗纖維化藥物、抗發炎藥物、皮質類固醇、免疫抑制劑等。吡非尼酮和尼達尼布等抗纖維藥物因其減緩疾病進展的能力而佔據主導地位。由於療效有限，皮質類固醇的使用率已下降，而硫唑嘌呤和嗎替麥考酚酯等免疫抑制劑則在特定病例中使用，通常與皮質類固醇一起使用。

2023 年，由於該病在 50 歲及以上人群中的患病率較高，成人細分市場的估值達到 20 億美元，引領市場。由於年齡是 IPF 發病的重要因素，因此老年人是治療的主要焦點。全球老化趨勢以及意識和診斷方面的進步進一步推動了該細分市場的成長。 NIH資料指出，雖然美國有 10 萬人受到 IPF 的影響，但其中絕大多數是 65 歲以上的成年人。

到 2032 年，北美特發性肺纖維化治療市場預計將達到 25 億美元，預測期內複合年成長率為 6.8%。美國在這​​個市場上佔據主導地位。導致美國 IPF 盛行率上升的因素包括人口老化、遺傳因素和環境影響。該地區先進的醫療基礎設施和強大的研發能力極大地塑造了特發性肺纖維化的治療模式。此外，製藥公司、研究實體和醫療保健專業人員之間的強大合作推動了創新並確保有效的治療可用性。隨著老年族群意識的提高和疾病發病率的上升，市場可望持續擴張。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • IPF 的發生率和盛行率不斷增加
      • 診斷技術的進步
      • 增強患者對 IPF 的認知
    • 產業陷阱與挑戰
      • 治療費用高
      • 功效有限且副作用大
  • 成長潛力分析
  • 監管環境
  • 未來市場趨勢
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

  • 主要趨勢
  • 藥品類
    • 抗纖維化藥物
    • 消炎劑
    • 皮質類固醇
    • 免疫抑制劑
    • 其他藥物類別
  • 治療
    • 氧氣治療
    • 肺康復
  • 肺移植

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

  • 主要趨勢
  • 口服
  • 注射用

第 7 章：市場估計與預測：按年齡分類，2021 - 2032

  • 主要趨勢
  • 成人
  • 老年科

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 醫院和診所
  • 門診手術中心 (ASC)
  • 家庭護理設置
  • 其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Service Provider
  • Medication Manufacturer
簡介目錄
Product Code: 11108

The Global Idiopathic Pulmonary Fibrosis Treatment Market was valued at USD 3 billion in 2023 and is projected to expand at a CAGR of 6.9% from 2024 to 2032. This growth is driven by the rising incidence of idiopathic pulmonary fibrosis (IPF), linked to aging populations and environmental factors.

As the global population ages, the prevalence of IPF challenges healthcare systems worldwide. Data from the National Institutes of Health shows IPF is more common in men, with North American rates ranging from 2.40 to 2.98 cases per 10,000 individuals. This prevalence has spurred innovations in treatment, including targeted therapies and immunotherapies, broadening patient care options and fueling market expansion.

Advances in diagnostic technologies have been crucial for the timely detection and management of IPF. Advanced imaging systems and non-invasive tools enable healthcare professionals to identify IPF earlier. Early detection allows for timely interventions, enhancing patient outcomes and driving market growth.

The overall idiopathic pulmonary fibrosis treatment industry is classified based on treatment type, route of administration, age group, end-use, and region.

In 2023, the drug class segment led the market with a valuation of USD 1.8 billion. This growth is due to increased awareness, timely diagnoses, and improved drug efficacy. NIH data indicates that around 100,000 individuals in the U.S. are diagnosed with IPF annually. The drug class segment includes antifibrotic drugs, anti-inflammatory drugs, corticosteroids, immunosuppressants, and others. Antifibrotic drugs like pirfenidone and nintedanib dominate due to their ability to slow disease progression. Corticosteroids have declined in preference due to limited effectiveness, while immunosuppressants such as azathioprine and mycophenolate mofetil are used in select cases, often alongside corticosteroids.

In 2023, the adult segment led the market with a valuation of USD 2 billion due to the disease's higher prevalence in those aged 50 and above. With age being a significant factor in IPF incidence, older adults are the primary focus for treatment. This segment's growth is further bolstered by the global aging trend and advancements in awareness and diagnostics. NIH data notes that while 100,000 people in the U.S. are affected by IPF, a significant majority are adults over 65.

North America idiopathic pulmonary fibrosis treatment market is set to reach USD 2.5 billion by 2032, with a projected CAGR of 6.8% over the forecast period. The U.S. commands a dominant position in this market. Factors contributing to the rising IPF prevalence in the U.S. include an aging demographic, genetic factors, and environmental influences. The region's advanced medical infrastructure and strong R&D capabilities significantly shape the IPF treatment landscape. Moreover, robust collaborations among pharmaceutical firms, research entities, and healthcare professionals drive innovation and ensure effective treatment availability. As awareness grows and the disease's incidence rises among older demographics, the market is poised for continued expansion.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence and prevalence of IPF
      • 3.2.1.2 Advancements in diagnostic techniques
      • 3.2.1.3 Enhanced patient awareness of IPF
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High treatment cost
      • 3.2.2.2 Limited efficacy and side effects
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Future market trends
  • 3.6 Pipeline analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Drug class
    • 5.2.1 Antifibrotic agents
    • 5.2.2 Anti-inflammatory
    • 5.2.3 Corticosteroids
    • 5.2.4 Immunosuppressants
    • 5.2.5 Other drug classes
  • 5.3 Therapy
    • 5.3.1 Oxygen therapy
    • 5.3.2 Pulmonary rehabilitation
  • 5.4 Lung transplantation

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oral
  • 6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Adult
  • 7.3 Geriatric

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Ambulatory surgical centers (ASCs)
  • 8.4 Homecare settings
  • 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Service Provider
    • 10.1.1 Bumrungrad International Hospital
    • 10.1.2 Cedars-Sinai
    • 10.1.3 Cleveland Clinic
    • 10.1.4 Dr. Sulaiman Al-Habib Medical Group
    • 10.1.5 Nicklaus Children's Hospital
  • 10.2 Medication Manufacturer
    • 10.2.1 Boehringer Ingelheim International GmbH
    • 10.2.2 Bristol-Myers Squibb Company
    • 10.2.3 Cipla Inc.
    • 10.2.4 F. Hoffmann-La Roche Ltd
    • 10.2.5 FibroGen, Inc.
    • 10.2.6 Galapagos NV
    • 10.2.7 Liminal BioSciences Inc.
    • 10.2.8 MediciNova, Inc.
    • 10.2.9 Novartis AG
    • 10.2.10 United Therapeutics